Article Information
History
- November 18, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Reiner Jumpertz von Schwartzenberg1,2,3,
- Norbert Stefan1,2,3,
- Robert Wagner2,4,5,
- Martina Guthoff1,2,3,
- Arvid Sandforth1,2,3,
- Andrea Icks2,6,7,
- Matthias Blüher2,8,
- Jochen Seissler2,9,
- Julia Szendrödi2,10,
- Michael Roden2,4,5,
- Christoph Wanner11,
- Hiddo J. L. Heerspink12,13,
- Hubert Preissl1,2,
- Andreas Fritsche1,2,3 and
- Andreas L. Birkenfeld1,2,3,*
- 1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
- 2German Center for Diabetes Research (DZD), Neuherberg, Germany
- 3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Clinic Tübingen, Tübingen, Germany
- 4Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
- 5Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
- 6Institute for Health Services Research and Health Economics, Centre for Health and Society, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- 7Institute for Health Services Research and Health Economics, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- 8Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany
- 9Diabetes Research Group, Medical Department 4, Ludwig-Maximilians University Munich, Munich, Germany
- 10Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Germany
- 11Division of Nephrology, University Hospital of Würzburg, Würzburg, Germany
- 12The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
- 13Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, Netherlands
- ↵*Corresponding author and delegated sponsor Prof. Dr. med. Andreas L. Birkenfeld Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University Hospital Tübingen Otfried-Müller-Str. 10 72076 Tübingen Germany E-mail: Andreas.birkenfeld{at}med.uni-tuebingen.de
Posted November 18, 2023.
SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) – rationale, methodology and design
